0001209191-17-022833.txt : 20170324 0001209191-17-022833.hdr.sgml : 20170324 20170324180031 ACCESSION NUMBER: 0001209191-17-022833 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170215 FILED AS OF DATE: 20170324 DATE AS OF CHANGE: 20170324 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Myovant Sciences Ltd. CENTRAL INDEX KEY: 0001679082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM 11 BUSINESS PHONE: (441) 824-8101 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM 11 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Takeda Pharmaceuticals International AG CENTRAL INDEX KEY: 0001688140 STATE OF INCORPORATION: V8 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 17713751 BUSINESS ADDRESS: STREET 1: THURGAUERSTRASSE 130 STREET 2: GLATTPARK-OPFIKON CITY: ZURICH STATE: V8 ZIP: 8152 BUSINESS PHONE: 41-44-555-10-00 MAIL ADDRESS: STREET 1: THURGAUERSTRASSE 130 STREET 2: GLATTPARK-OPFIKON CITY: ZURICH STATE: V8 ZIP: 8152 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-15 0 0001679082 Myovant Sciences Ltd. MYOV 0001688140 Takeda Pharmaceuticals International AG THURGAUERSTRASSE 130 GLATTPARK-OPFIKON ZURICH V8 8152 SWITZERLAND 0 0 1 0 Common Shares 2017-02-15 4 M 0 6845 0.00 A 7403102 D Common Shares 2017-03-15 4 M 0 13091 0.00 A 7416193 D Warrant to Purchase Common Shares 2017-02-15 4 M 0 6845 0.00 D Common Shares 6845 0 D Warrant to Purchase Common Shares 2017-03-15 4 M 0 13091 0.00 D Common Shares 13091 0 D $0.000017727 per share. At any time following the Issuer's issuance of any class of capital shares, if necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership in the Issuer, as determined after such exercise. Upon the earlier of (A) April 30, 2017 and (B) a change of control of the Issuer, unless such change in control results in a privately-held entity in which the holders of 40% or more of the equity securities, calculated on a fully-diluted basis, of the surviving entity are held by persons and entities who were affiliates of the Issuer prior to such change in control. An indeterminate number of capital shares necessary to allow the Reporting Person, together with its affiliates, to maintain a 12% ownership interest in the Issuer, as determined after such exercise. /s/Alison Haggerty, Attorney-in-Fact 2017-03-24